Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade

INTRODUCTION: It is unclear whether polymyalgia rheumatica (PMR) should be considered an inflammatory disease or an autoimmune disease. METHODS: Eighteen untreated early PMR patients and 18 sex- and age-matched healthy controls (HCs) were included. PMR patients received tocilizumab from week 0 to we...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvajal Alegria, Guillermo, Cornec, Divi Y. K., Renaudineau, Yves, Saraux, Alain, Devauchelle-Pensec, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981388/
https://www.ncbi.nlm.nih.gov/pubmed/33745124
http://dx.doi.org/10.1007/s40744-021-00299-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981388/
https://www.ncbi.nlm.nih.gov/pubmed/33745124
http://dx.doi.org/10.1007/s40744-021-00299-8

Ejemplares similares